Showing results (31-40 of 678) with videos related to
Sort By:
Pageof 68
Biologics : Targets & Therapy|January 19, 2026
Teclistamab for Relapsed or Refractory Multiple Myeloma: A Review of Efficacy, Safety, Resistance Mechanisms and Future DirectionsBénédicte Piron, Philippe Moreau, Cyrille TouzeauFuture Oncology (London, England)|December 8, 2020
Carfilzomib in combination with daratumumab in the management of relapsed multiple myelomaCyrille Touzeau, Chloé Antier, Philippe MoreauExpert Review of Hematology|February 9, 2018
The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in EuropeMichele Cavo, Evangelos Terpos, Joan Bargay, et al.Expert Review of Clinical Immunology|July 5, 2016
The role of SLAMF7 in multiple myeloma: impact on therapyJean-Samuel Boudreault, Cyrille Touzeau, Philippe MoreauExpert Review of Hematology|January 24, 2017
Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trialsJean-Samuel Boudreault, Cyrille Touzeau, Philippe MoreauJournal of Cellular and Molecular Medicine|June 11, 2009
Non-classical transcriptional regulation of HLA-G: an updatePhilippe Moreau, Sébastien Flajollet, Edgardo D CarosellaBlood Cancer Journal|March 22, 2019
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomidePhilippe Moreau, Elena Zamagni, Maria-Victoria MateosExpert Opinion on Investigational Drugs|July 13, 2021
Immune checkpoint inhibitors for the treatment of myeloma: novel investigational optionsBaptiste Le Calvez, Philippe Moreau, Cyrille TouzeauOptics Express|August 10, 2017
Optimizing the metric in sensorless adaptive optical microscopy with fluorescence fluctuationsJoseph Gallagher, Antoine Delon, Philippe Moreau, et al.Advances in Therapy|September 29, 2016
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European PerspectiveJesus F San-Miguel, Hermann Einsele, Philippe MoreauPageof 68